Korro Bio (KRRO) Stock Price, News & Analysis

Company Overview

Korro Bio, Inc. is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company’s approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient’s DNA.

Korro Bio’s technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease. The program is intended to edit disease-associated RNA and promote production of functional alpha-1 antitrypsin protein.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Korro Bio conducts research and drug development in the United States. The company has focused on advancing its RNA editing platform and pipeline through preclinical and clinical development; it does not have a broadly marketed commercial product based on the information available.

Key Stats

• Today's Range: $14.80 to $15.70
• 50-Day Range: $8.49 to $16.62
• 52-Week Range: $5.20 to $33.92
• Volume: 128,858 shs
• Average Volume: 194,943 shs
• Market Capitalization: $221.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Moderate Buy

Korro Bio Stock Analysis - MarketRank™

Korro Bio scored higher than 40% of companies evaluated by MarketBeat, and ranked 729th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Korro Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 3 strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Korro Bio is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Korro Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Korro Bio are expected to grow in the coming year, from ($4.80) to ($4.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Korro Bio is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Korro Bio is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Korro Bio has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.48% of the float of Korro Bio has been sold short.

Short Interest Ratio / Days to Cover

Korro Bio has a short interest ratio ("days to cover") of 8.18.

Change versus previous month

Short interest in Korro Bio has recently increased by 0.94%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Korro Bio does not currently pay a dividend.

Dividend Growth

Korro Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.70

News Sentiment

Korro Bio has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Korro Bio this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for KRRO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $352,855.00 in company stock, which represents 0.1540% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Korro Bio insiders have bought 66.32% more of their company's stock than they have sold. Specifically, they have bought $884,919.00 in company stock and sold $532,064.00 in company stock.

Percentage Held by Insiders

4.80% of the stock of Korro Bio is held by insiders.

Percentage Held by Institutions

13.18% of the stock of Korro Bio is held by institutions.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/11/2026
• Jefferies Global Healthcare Conference: 11/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KRRO
• Previous Symbol: NASDAQ:KRRO
• CIK: 1703647
• Web: www.korrobio.com
• Phone: 781-315-4600
• Fax: N/A
• Employees: 57
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Korro Bio: $16.50
• High Price Target: $23.00
• Low Price Target: $10.00
• Potential Upside/Downside: +9.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$117.26 million
• Net Margins: N/A
• Pretax Margin: -8,129.41%
• Return on Equity: -117.06%
• Return on Assets: -69.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.30
• Quick Ratio: 7.30

Sales & Book Value

• Annual Sales: $1.29 million
• Price / Sales: 171.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.44 per share
• Price / Book: 2.34

Miscellaneous

• Outstanding Shares: 14,726,000
• Free Float: 14,019,000
• Market Cap: $221.64 million
• Optionable: Optionable
• Beta: 3.23